Latest stories on COYA
Coya Therapeutics, Inc. (COYA) files 8-K
SEC 8-K50 · neutralgeneral
Coya Therapeutics announces 100th patient enrolled in Phase 2/3 ALSTARS trial
The Fly63 · neutralproduct/pr
Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
StockTitan67 · bullishproduct/pr
Coya announces publication of preclinical study on effects of COYA 303
The Fly59 · neutralproduct/pr
H.C. Wainwright reiterates Coya Therapeutics stock rating at buy
Investing.com Analyst Ratings61 · neutralanalyst
Coya Therapeutics Reports Q2 Eps 28c Consensus 36c
The Fly34 · bearishearnings
Coya Therapeutics GAAP EPS of -$0.28 beats by $0.07, revenue of $0.24M beats by $0.14M
Seeking Alpha56 · neutralearnings
Coya Therapeutics, Inc. (COYA) files 8-K
SEC 8-K50 · neutralgeneral
Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
StockTitan50 · neutralgeneral
8-K/A - Coya Therapeutics, Inc. (COYA) files 8-K
SEC 8-K50 · neutralgeneral
Coya Therapeutics, Inc. (COYA) files 8-K
SEC 8-K50 · neutralgeneral
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting | COYA Stock News
StockTitan56 · neutralproduct/pr
Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit | COYA Stock News
StockTitan56 · neutralproduct/pr